Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting
-- Company to host key opinion leader webinar today, October 1, at 10:00am ET --LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing
United Kingdom United States Kostenloser Wertpapierhandel Ashley Robinson Amolyt Pharma Thierry Abribat
Source: finanznachrichten.de